Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study

Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)

NCT00706342 ·Status: COMPLETED ·Phase: PHASE2

Special Drug Use-results Survey for Long-term Use (Fostamatinib)

NCT06757257 ·Status: RECRUITING

Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

NCT03363334 ·Status: NO_LONGER_AVAILABLE

Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

NCT04543279 ·Status: TERMINATED ·Phase: PHASE2

A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)

NCT04021173 ·Status: UNKNOWN ·Phase: PHASE2

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

NCT03952039 ·Status: COMPLETED ·Phase: PHASE3

Immunological Markers in Adult Patients With Immune Thrombocytopenic Purpura

NCT04056507 ·Status: COMPLETED

The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.

NCT01101295 ·Status: UNKNOWN

Avatrombopag to Promote Platelet Engraftment After Allo-HSCT

NCT05143892 ·Status: UNKNOWN ·Phase: PHASE2

Avatrombopag Combined With IST as First-line Treatment for SAA

NCT05720234 ·Status: UNKNOWN ·Phase: PHASE2

Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function

NCT05571332 ·Status: UNKNOWN ·Phase: NA

Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)

NCT06287567 ·Status: COMPLETED ·Phase: PHASE2

Biologic Characterization of Patients With ITP

NCT05694325 ·Status: RECRUITING ·Phase: NA

Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

NCT04638829 ·Status: COMPLETED ·Phase: PHASE4

The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients

NCT03951623 ·Status: COMPLETED ·Phase: PHASE1

Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00540423 ·Status: COMPLETED ·Phase: PHASE3

An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)

NCT01129024 ·Status: TERMINATED ·Phase: PHASE2

Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP

NCT07057778 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

NCT07206758 ·Status: RECRUITING ·Phase: PHASE1

A Study of Orelabrutinib in Patients With ITP

NCT05124028 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001

NCT03041909 ·Status: COMPLETED ·Phase: PHASE2

Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT

NCT01652599 ·Status: COMPLETED ·Phase: PHASE2

Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia

NCT05325593 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery

NCT06673498 ·Status: RECRUITING ·Phase: PHASE2

Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe

NCT06408324 ·Status: COMPLETED